TrialProstate cancer and prostatic diseases2011

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.

K Izumi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.